{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA), Table 1",
        "description": "Reference from the Protocol Amendment Summary to Section 8, which details procedures specific to screening sites in the US."
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2.3.1.1",
        "sectionTitle": "Coronavirus (SARS-CoV-2) Disease 2019",
        "description": "Reference to Section 10.5 for potential risks and mitigation measures due to the COVID-19 vaccine."
      },
      {
        "id": "ref_3",
        "name": "Dose Modification Reference in Risk Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 3",
        "sectionTitle": "Potential Risks and Mitigation Strategy",
        "description": "Reference to Section 6.6 for dose modification or discontinuation as a mitigation strategy for various potential risks."
      },
      {
        "id": "ref_4",
        "name": "Investigator's Brochure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 3",
        "sectionTitle": "Potential Risks and Mitigation Strategy",
        "description": "Reference to the Investigator's Brochure (IB) for data on ALXN1840 and ammonium tetrathiomolybdate studies."
      },
      {
        "id": "ref_5",
        "name": "Adaptive Design Features Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Overall Design",
        "description": "Reference to Table 4 for a description of adaptive protocol features and their limits."
      },
      {
        "id": "ref_6",
        "name": "Dose Modification Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference to Table 7 for criteria on when a dose should be decreased or interrupted."
      },
      {
        "id": "ref_7",
        "name": "Investigator's Brochure Reference for Rationale",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.2",
        "sectionTitle": "Scientific Rationale for Study Design",
        "description": "Reference to the current Investigator's Brochure (IB) regarding nonclinical data on copper elimination."
      },
      {
        "id": "ref_8",
        "name": "Blood Donation Restriction Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Lifestyle Considerations",
        "description": "Reference to Section 5.2 from Table 5 regarding restrictions on blood donation prior to screening."
      },
      {
        "id": "ref_9",
        "name": "Contraception Methods Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Lifestyle Considerations",
        "description": "Reference to Section 10.4 for a description of appropriate contraceptive methods."
      },
      {
        "id": "ref_10",
        "name": "Contraception Start Time Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Lifestyle Considerations",
        "description": "Reference to Section 5.1 (inclusion criteria) for start times for contraceptive use."
      },
      {
        "id": "ref_11",
        "name": "Intervention Discontinuation Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Reference to the Schedule of Activities (SoA, Section 1.3) for data to be collected at the time of study intervention discontinuation."
      },
      {
        "id": "ref_12",
        "name": "Pregnancy Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.1",
        "sectionTitle": "Discontinuation of Study Intervention",
        "description": "Reference to Section 8.2.6 regarding discontinuation from study intervention due to pregnancy."
      },
      {
        "id": "ref_13",
        "name": "Participant Withdrawal Procedures",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2",
        "sectionTitle": "Participant Discontinuation/Withdrawal From the Study",
        "description": "Reference to the Schedule of Activities (SoA, Section 1.3) for data to be collected at the time of study discontinuation."
      },
      {
        "id": "ref_14",
        "name": "ECG Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.3",
        "sectionTitle": "Electrocardiograms",
        "description": "Reference to Section 7 for QTc withdrawal criteria."
      },
      {
        "id": "ref_15",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.4",
        "sectionTitle": "Clinical Safety Laboratory Assessments",
        "description": "Reference to Section 10.2 for the list of clinical laboratory tests to be performed."
      },
      {
        "id": "ref_16",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3",
        "sectionTitle": "Adverse Events and Serious Adverse Events",
        "description": "Reference to Section 10.3 for procedures on recording, evaluating, follow-up, and reporting AEs and SAEs."
      },
      {
        "id": "ref_17",
        "name": "Lost to Follow-up Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.3",
        "sectionTitle": "Follow-up of AEs and SAEs",
        "description": "Reference to Section 7.3 for the definition of 'lost to follow-up'."
      },
      {
        "id": "ref_18",
        "name": "Genetic Testing Non-use Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.6",
        "sectionTitle": "Retained and Biobanked Sample",
        "description": "Reference to Section 8.7 clarifying that biobanked samples will not be used for genetic testing."
      },
      {
        "id": "ref_19",
        "name": "Pharmacokinetics Sample Collection Schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "Reference to the SoA (Table 1) for the schedule of whole blood sample collection for PK measurements."
      },
      {
        "id": "ref_20",
        "name": "Molybdenum Measurement Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.5",
        "sectionTitle": "Pharmacokinetics",
        "description": "Reference to Section 8.1.1 for details of molybdenum measured in food, drinks, urine, and feces."
      },
      {
        "id": "ref_21",
        "name": "Pharmacodynamics Sample Collection Schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference to the SoA (Table 1) for the schedule of blood sample collection for PD assessments."
      },
      {
        "id": "ref_22",
        "name": "Biomarker Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.8",
        "sectionTitle": "Biomarkers",
        "description": "Reference to Section 8.6 and Section 8.1.1 for details of copper and other biomarker measurements."
      },
      {
        "id": "ref_23",
        "name": "Analysis Populations Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.3",
        "sectionTitle": "Populations for Analyses",
        "description": "Reference to Table 8 for the definitions of the population sets used for analyses."
      },
      {
        "id": "ref_24",
        "name": "ECG Analysis Time Points",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.4.3",
        "sectionTitle": "Safety Analyses",
        "description": "Reference to the SoA (Table 1) for specified time points for ECG parameter measurements."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Addition of text to the footnote to state that procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Current protocol version. Clarifies study procedures in the US to facilitate participant recruitment.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous approved protocol amendment.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous approved protocol amendment.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous approved protocol amendment.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original approved protocol.",
        "amendmentNumber": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 24,
      "annotationCount": 4,
      "versionCount": 5
    }
  }
}